WAVE Life Sciences Ltd. WVE
- Market cap
- $780.3M
- P/E
- 0.0×
Follow WVE
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8.95 | 15.15 | 31.65 | 7.78 | 6.61 | 3.07 | 1.16 | 3.15 | 3.50 | 5.28 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| 40.15 | 39.70 | 56.00 | 48.64 | 19.98 | 12.17 | 7.09 | 7.12 | 16.74 | 21.73 |
High Price
|
|||
| 96 | 168 | 250 | 301 | 220 | 238 | 252 | 268 | 288 | 317 |
Employees
|
|||
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue/Emp
|
|||
| 1 | 4 | 14 | 16 | 20 | 41 | 4 | 113 | 108 | 43 |
Revenue
|
|||
| 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
Gross Margin
|
|||
| (55) | (101) | (147) | (194) | (151) | (122) | (161) | (58) | (97) | (204) |
EBT
|
|||
| (5,052.93%) | (2,597.95%) | (1,016.96%) | (1,211.52%) | (750.86%) | (298.92%) | (4,416.06%) | (51.36%) | (89.57%) | (478.33%) |
EBT Margin
|
|||
| (56) | (102) | (147) | (194) | (150) | (122) | (162) | (58) | (97) | (204) |
Net Income
|
|||
| 1 | 2 | 5 | 9 | 10 | 10 | 10 | 9 | 9 | 9 |
Depreciation
|
|||
| 0.05 | 0.15 | 0.50 | 0.47 | 0.51 | 0.79 | 0.05 | 1.07 | 0.78 | 0.25 |
Revenue/Sh
|
|||
| (2.43) | (3.85) | (5.06) | (5.72) | (3.82) | (2.36) | (2.05) | (0.54) | (0.70) | (1.21) |
Earnings/Sh
|
|||
| (1.40) | (3.16) | (0.79) | (5.56) | (2.96) | (1.72) | (1.62) | (0.18) | (1.09) | (1.11) |
Cash Flow/Sh
|
|||
| (0.24) | (0.71) | (0.34) | (0.12) | (0.03) | (0.01) | (0.02) | (0.01) | (0.01) | 0.00 |
Capex/Sh
|
|||
| (1.64) | (3.87) | (1.13) | (5.67) | (2.99) | (1.73) | (1.64) | (0.19) | (1.10) | (1.12) |
Free CF/Sh
|
|||
| 6.26 | 5.56 | 2.53 | 1.88 | 2.11 | 0.63 | (0.57) | 0.37 | 1.52 | 3.07 |
Book Value/Sh
|
|||
| 23 | 27 | 29 | 34 | 39 | 52 | 79 | 106 | 138 | 169 |
Shares
|
|||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
PE Ratio
|
|||
| 547.06 | 237.00 | 84.49 | 16.99 | 15.38 | 3.23 | 133.98 | 5.00 | 15.79 | 67.10 |
PS Ratio
|
|||
| 4.43 | 6.61 | 16.60 | 4.26 | 3.73 | 5.01 | 0.00 | 14.30 | 8.16 | 5.53 |
PB Ratio
|
|||
| 409.44 | 201.19 | 73.01 | 9.62 | 7.46 | 0.74 | 118.53 | 3.47 | 13.26 | 53.65 |
EV/Sales
|
|||
| (11.93) | (7.64) | (32.08) | (0.80) | (1.28) | (0.41) | (3.35) | (19.15) | (9.45) | (12.18) |
EV/FCF
|
|||
| (32) | (84) | (23) | (188) | (116) | (89) | (128) | (19) | (151) | (187) |
Op' Cash Flow
|
|||
| (6) | (19) | (10) | (4) | (1) | (1) | (1) | (1) | (1) | (1) |
Capex
|
|||
| (37) | (103) | (33) | (192) | (117) | (90) | (129) | (21) | (152) | (188) |
FCF
|
|||
| 140 | 132 | 72 | 67 | 109 | 98 | 27 | 49 | 209 | 520 |
Working Cap'
|
|||
| 0 | 3 | 9 | 29 | 26 | 25 | 32 | — | — | — |
Total Debt
|
|||
| (150) | (139) | (166) | (118) | (159) | (126) | (56) | (200) | (302) | (602) |
Net Debt
|
|||
| 143 | 147 | 73 | 64 | 83 | 32 | (45) | 40 | 210 | 518 |
Sh' Equity
|
|||
| (33.71%) | (58.84%) | (61.39%) | (66.75%) | (53.21%) | (50.28%) | (91.58%) | (27.30%) | (30.94%) | (41.26%) |
ROA
|
|||
| 0.00% | (792.50%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
ROIC
|
|||
| (38.61%) | (74.31%) | (137.73%) | (282.52%) | (204.64%) | (212.09%) | 2,570.05% | 2,106.32% | (77.87%) | (56.16%) |
ROE
|
|||
WAVE Life Sciences Ltd. peers in Biotechnology
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| GYRE Gyre Therapeutics, Inc. | $777.2M | 0.0× | Compare |
| OLMA Olema Pharmaceuticals, Inc. | $791.0M | 0.0× | Compare |
| IVA Inventiva S.A. Sponsored ADR | $767.8M | 0.0× | Compare |
| SLDB Solid Biosciences Inc. | $802.0M | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| FDMT 4D Molecular Therapeutics, Inc. | $807.1M | 0.0× | Compare |
| DSGN Design Therapeutics, Inc. | $809.3M | 0.0× | Compare |
| FTH Faeth Therapeutics, Inc. | $750.7M | 0.0× | Compare |
| ACHV Achieve Life Sciences, Inc. | $814.0M | 0.0× | Compare |
WAVE Life Sciences Ltd. (WVE) key facts
- WAVE Life Sciences Ltd. (WVE) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of September 25, 2026, WVE traded at $3.78, a market capitalization of $780.3 million.
- Return on equity was −56.2% and debt-to-equity 0.00.
WAVE Life Sciences Ltd. (WVE) Latest News
23 Sep
Wave Life Sciences launched a Phase 2a trial of WVE-007, its INLIGHT GalNAc-siRNA, in combination with tirzepatide for obesity. The placebo-controlled study tests 240 mg and 400 mg WVE-007 with weekly tirzepatide in 240 adults with obesity (BMI 35-50) and type 2 diabetes. Wave plans three development settings for WVE-007: monotherapy, combination with incretins, and a maintenance therapy to prevent weight regain after stopping incretin treatment, with a maintenance trial expected in 2H 2026. Preclinical data suggest INHBE silencing with GLP-1s could double weight loss versus GLP-1 alone, while preserving muscle and enabling once- or twice-yearly dosing. The INLIGHT program also includes other cardiometabolic indications, including MASH, and Wave cites potential synergistic effects with GLP-1s and favorable safety. Wave remains focused on advancing WVE-007 across obesity and related diseases. Phase 2a combination trial with tirzepatide expands WVE-007's development path and could meaningfully affect obesity treatment readouts and investor sentiment.
22 Sep
Wave Life Sciences Ltd. announced the appointment of Monika Vnuk, MD, as Chief Business Officer, a newly created role to lead business development, corporate development, and alliance management. Vnuk, formerly Sanofi's Senior VP and Global Head of Partnering and BD, also held senior posts at Blackstone Life Sciences and Pfizer, including guiding the BioNTech COVID-19 vaccine partnership. She joins Wave's executive team as the company advances its RNA medicines pipeline. Wave granted Vnuk a stock option to buy 375,000 shares at $4.25, vesting over four years. CEO Paul Bolno said the hire supports growth and value-creating transactions, while Vnuk emphasized leveraging Wave's platform and pipeline to expand partnerships. Wave's portfolio includes obesity program WVE-007, A1AT deficiency program WVE-006, PNPLA3 liver disease program WVE-008, plus Duchenne and Huntington's disease programs. Dr. Vnuk's appointment brings broad BD/financing experience from Sanofi, Blackstone, and Pfizer, signaling a strategy to expand partnerships and asset financing.
13 Aug
Wave Life Sciences Ltd. (WVE) is positioned as a $1 billion RNA-medicine company attractive for potential pharma takeover. Potential acquisition interest would drive major shifts in company trajectory and investor sentiment.
7 Aug
Wave Life Sciences completed U.S. redomiciliation and reported mixed first-half 2026 results, prompting questions over shifts in its investment narrative. U.S. redomiciliation marks a major strategic move paired with mixed 2026 results that could reshape Wave Life Sciences' operational structure and market trajectory.
3 Aug
Wave Life Sciences Ltd. held its Q2 2026 earnings call to review financial results and company updates. Earnings call delivers financial metrics and pipeline status that moderately shift investor views on near-term performance.
30 Jul
Wave Life Sciences Ltd. (WVE) held its Q2 2026 earnings call covering financial results, pipeline progress, and operational updates. Quarterly earnings call supplies performance data and guidance that can shift near-term investor views but rarely transforms core trajectory.
Wave Life Sciences Ltd. held its Q2 2026 earnings call covering financial results, pipeline updates and operational outlook. Q2 2026 earnings call delivers financial metrics and pipeline updates that moderately influence Wave Life Sciences Ltd. outlook.
WAVE Life Sciences reported Q2 financial results during its earnings call, highlighting pipeline progress in RNA therapeutics for neuromuscular and genetic diseases along with cash position and upcoming milestones. Q2 earnings and pipeline updates offer moderate insights into operations and outlook without major strategic shifts.
WAVE Life Sciences Ltd highlighted strong cash position and other updates in its Q2 2026 earnings call. Strong cash position provides operational runway but represents standard earnings update without major strategic shifts.
Takeda Pharmaceutical Q1 earnings call highlighted collaboration progress with WAVE Life Sciences on RNA therapeutics programs including Huntington's disease candidates. Takeda partnership updates can moderately shift WVE development timelines and investor views but are unlikely to redefine core trajectory.
Wave Life Sciences Ltd. reported second quarter 2026 financial results and provided a business update. Quarterly results and updates offer performance data that can shift near-term investor sentiment without major strategic overhaul.
22 Jul
Wave Life Sciences (WVE) upgraded to Strong Buy rating, signaling potential positive effects on stock performance and investor interest. Analyst upgrade to Strong Buy may boost short-term market sentiment and share price without altering core operations.
30 Jun
Wave Life Sciences initiates multidose Phase 2a portion of INLIGHTTM trial. Phase 2a trial start advances pipeline but does not guarantee near-term commercial results.
24 Jun
Wave Life Sciences initiates Phase 2a portion of INLIGHT trial for WVE-007 INHBE GalNAc-siRNA in obesity and cardiometabolic diseases. Phase 2a start advances obesity candidate WVE-007 and signals major clinical development progress.
16 Jun
Wave Life Sciences (WVE) receives analyst upgrade to Buy rating on improved outlook and prospects. Buy rating upgrade directly lifts investor sentiment and near-term stock trajectory for Wave Life Sciences.
25 May
WVE-006 RNA-editing AAT data prompts reevaluation of risk-reward profile for Wave Life Sciences investors. WVE-006 AAT RNA-editing data directly affects Wave Life Sciences core pipeline prospects and investor sentiment.
19 May
Wave Life Sciences supports AlphaDetect to accelerate detection of Alpha-1 antitrypsin deficiency. Backing faster Alpha-1 detection may expand the addressable patient pool for Wave's therapies.
18 May
Wave Life Sciences reports WVE-006 achieved MZ-like phenotype in RestorAATion-2 trial under both biweekly and monthly dosing. Positive clinical data on lead RNA-editing candidate strengthens pipeline prospects and supports future valuation upside.
8 May
Industry analysts upgraded revenue forecasts for Wave Life Sciences Ltd. (NASDAQ: WVE) by 91%, signaling strong growth potential for investors. 91% revenue forecast upgrade by analysts indicates significant positive shift in market sentiment and potential stock performance boost.
29 Apr
Wave Life Sciences Ltd. Q1 2026 earnings call summary highlights financial results, pipeline updates, and strategic outlook for the biotech firm. Q1 2026 earnings disclosure covers financial performance, clinical progress, and guidance that could substantially shift investor sentiment and company valuation.
WAVE Life Sciences Ltd. (WVE) Q1 2026 earnings call highlights revenue surge alongside strategic advancements. Revenue surge in Q1 2026 earnings signals major financial improvement and strategic shifts boosting WVE's trajectory.
28 Apr
WAVE Life Sciences Ltd. (WVE) Q1 earnings call highlights financial results, clinical pipeline updates, and strategic priorities amid ongoing biotech developments. Q1 earnings highlights cover financials, pipeline progress, and strategies with potential to significantly shift investor sentiment and company trajectory.
Wave Life Sciences (WVE) reported a Q1 net loss but exceeded revenue estimates. Quarterly earnings showing revenue beat despite loss moderately impacts financial perception and short-term market sentiment.
Wave Life Sciences Ltd. (WVE) reported first quarter 2026 financial results and provided a business update. Quarterly financial results and business updates moderately influence financial performance and investor sentiment.
21 Apr
Wave Life Sciences Ltd. (WVE) announces a hearing on its proposed redomiciliation from Bermuda to the United States, aiming to establish U.S. incorporation for strategic benefits. Redomiciliation to the US constitutes a major strategic relocation enhancing access to U.S. capital markets, regulatory alignment, and investor preference.
20 Apr
H.C. Wainwright warns investors misread Wave Life Sciences Ltd. (WVE) clinical data, causing overreaction and sell-off, while data supports positive efficacy and safety, presenting buying opportunity. Analyst rebuttal of negative clinical data reaction signals potential stock rebound and sentiment shift core to WVE's biotech trajectory.
15 Apr
Wave Life Sciences Ltd. announces proposed redomiciliation from Singapore to the United States to streamline operations, enhance U.S. capital market access, attract talent, and position for growth. The transaction requires shareholder approval and is targeted for completion in early 2025, with no changes to headquarters, employees, or business. Redomiciliation to the US represents a major strategic shift improving governance, investor access, and long-term growth prospects.
31 Mar
Wave Life Sciences Ltd. (WVE) unveiled obesity program data prioritizing visceral fat reduction over total weight loss, demonstrating superior efficacy in metabolically harmful fat deposits compared to weight-focused metrics. Obesity data spotlighting visceral fat reduction offers WVE a differentiated profile in the competitive GLP-1 dominated market, likely boosting investor sentiment and pipeline value.
30 Mar
Canaccord Genuity raised its price target for Wave Life Sciences Ltd. (WVE) to $52 from a prior level following a positive pipeline review. Price target increase to $52 after pipeline review signals strong analyst confidence, likely enhancing investor sentiment and stock trajectory.
27 Mar
Wave Life Sciences Ltd. (WVE) stock plunged deep into oversold territory after disappointing obesity drug data, prompting debate on whether to buy the dip. Disappointing obesity drug data drove WVE stock into oversold territory, signaling significant setback to pipeline progress and investor sentiment.